All articles tagged with #bridgebio
BridgeBio Pharma's stock surged over 23% after receiving FDA approval for its heart disease drug, acoramidis, which will compete with Pfizer's Vyndaqel. The approval came earlier than expected, allowing BridgeBio to market acoramidis under the brand name Attruby for treating transthyretin amyloid cardiomyopathy (ATTR-CM).
The FDA has approved BridgeBio's new drug, Attruby, for treating transthyretin amyloid cardiomyopathy (ATTR-CM), marking the first new treatment for this heart condition in over five years. ATTR-CM, which affects over 400,000 people globally, is caused by genetic mutations or aging, leading to amyloid deposits in the heart that impair its function. This approval represents BridgeBio's first major commercial product.
The FDA has approved BridgeBio's drug acoramidis for treating a rare genetic heart disease, setting the stage for market competition with companies like Pfizer and Alnylam.
Biotech company BridgeBio is set to receive approximately $250 million through a private investment in public equity (PIPE) as it approaches the submission for approval of its heart pill, acoramidis. This comes two months after the company announced positive Phase III results, which caused its shares to surge by 50%. The PIPE will bring in new long-term shareholders and addresses the question of BridgeBio's financial strategy following its recent success.
BridgeBio has announced positive results from its Phase III trial of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The trial showed improvements in mortality, cardiovascular-related hospitalizations, a six-minute walk test, and a biomarker of the disease. Patients receiving the drug had an 81% survival rate at 30 months, compared to 74% on placebo, and the drug reduced hospitalization rates by 50%.